NEFL Primary Antibody
|Aliases||NFL; NF-L; NF68; CMT1F; CMT2E|
|Formulation||Ascitic fluid containing 0.03% sodium azide|
|Immunogen||Purified recombinant fragment of human NEFL expressed in E. Coli.|
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|ICC (Immunocytochemistry)||1/200 - 1/1000|
|IHC_P(Immunohistochemistry)||1/200 - 1/1000|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Contact us to order
Figure 1: Western blot analysis using NEFL mAb against human NEFL (AA: 422-543) recombinant protein. (Expected MW is 62 kDa)
Figure 2: Western blot analysis using NEFL mouse mAb against Hela (1) and Jurkat (2) cell lysate.
Figure 3: Immunofluorescence analysis of Hela cells using NEFL mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.
Figure 3: Immunohistochemical analysis of paraffin-embedded lung cancer tissues using NEFL mouse mAb with DAB staining.
Figure 4: Flow cytometric analysis of Jurkat cells using NEFL mouse mAb (green) and negative control (red).
Figure 4: Immunohistochemical analysis of paraffin-embedded bladder cancer tissues using NEFL mouse mAb with DAB staining.
Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
Neurofilaments are type IV intermediate filament heteropolymers composed of light, medium, and heavy chains. Neurofilaments comprise the axoskeleton and they functionally maintain the neuronal caliber. They may also play a role in intracellular transport to axons and dendrites. This gene encodes the light chain neurofilament protein. Mutations in this gene cause Charcot-Marie-Tooth disease types 1F (CMT1F) and 2E (CMT2E), disorders of the peripheral nervous system that are characterized by distinct neuropathies. A pseudogene has been identified on chromosome Y.
|References (references)||1. BMB Rep. 2008 Dec 31;41(12):868-74.|
2. J Hum Genet. 2009 Feb;54(2):94-7.